NCT07885306Active, not recruitingPhase 1
Safety and Preliminary Antitumor Activity of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
A Phase 1a, Open-Label, Dose-Escalation Study of Ivonescimab in Combination With Pemetrexed and Platinum-Based Chemotherapy as First-Line Treatment in Patients With Advanced Malignant Pleural Mesothelioma
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
This Phase 1a, open-label, dose-escalation study evaluates the safety, tolerability, and preliminary antitumor activity of ivonescimab in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced malignant pleural mesothelioma. Ivonescimab is evaluated at sequential dose levels of 3, 10, and 20 mg/kg using a 3+3 dose-escalation design.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- First submitted
- 11 Oct 2026
- Start date
- 12 Mar 2025
- Primary completion date
- 13 Aug 2026
- Lead sponsor
- Ruijin Hospital
- Diseases
- Mesothelioma, Lung cancer
- NCT number
- NCT07885306
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 9
- From 12 Mar 2025 to the primary completion date, 13 Aug 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active autoimmune disease requiring systemic treatment or other contraindications to immunotherapy.
- Uncontrolled hypertension, significant bleeding risk, or other contraindications to antiangiogenic therapy.
- Active interstitial lung disease or noninfectious pneumonitis.
- Active infection requiring systemic treatment.
- Other active malignancies requiring anticancer treatment.
- Severe uncontrolled medical conditions that may interfere with study treatment.
Other
- Pregnant or breastfeeding women.
Who the study is looking for
- Age 18 to 75 years.
- Histologically confirmed advanced or metastatic malignant pleural mesothelioma not amenable to surgery.
- No prior systemic anticancer therapy for advanced disease.
- ECOG PS 0-1.
- At least one measurable lesion according to modified RECIST (mRECIST).
- Adequate organ function for study treatment.
- Patients with asymptomatic or stable brain metastases are eligible.
- Able to understand the study, provide written informed consent, and comply with study procedures.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| West China Hospital of Sichuan University Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
| The First Affiliated Hospital of Guangzhou Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| Shanghai Chest Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.